Ascrinvacumab
Source: Wikipedia, the free encyclopedia.
Chemical compound
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | activin receptor-like kinase 1 |
Clinical data | |
Other names | PF-03446962 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6396H9850N1694O2012S44 |
Molar mass | 144079.64 g·mol−1 |
Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.[1]
This drug was developed by Pfizer Inc.
References
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
---|---|---|---|---|---|---|---|---|---|
Bone |
| ||||||||
Musculoskeletal |
| ||||||||
Circulatory |
| ||||||||
Neurologic |
| ||||||||
Angiogenesis inhibitor |
| ||||||||
Growth factor |
| ||||||||
|